Topic: Herbert Lepor
Quanterix, a diagnostics startup in Cambridge, MA, has developed a highly sensitive new technology capable of detecting a single, cancer-linked molecule in blood, to predict the recurrence of prostate cancer. Researchers found that while commercial assays detected no PSA in any of ...